IPO-38 Antibody [IPO-38] | 33-527

IPO-38 Antibody [IPO-38] | 33-527 | Gentaur UK, US & Europe Distribution

Host: Mouse

Reactivity: Human, Mouse, Rat

Homology: N/A

Immunogen: Spleen cells from a patient with hairy cell leukemia were used as the immunogen for the IPO-38 antibody.

Research Area: Cancer

Tested Application: Flow, IF, IHC-P

Application: Flow Cytometry: 0.5-1 ug/million cells in 0.1ml
Immunofluorescence: 0.5-1 ug/ml
Immunohistochemistry (FFPE) : 0.5-1 ug/ml for 30 min at RT (1)
Prediluted format: incubate for 30 min at RT (2)
Optimal dilution of the IPO-38 antibody should be determined by the researcher.

1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 min.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required) , drip mAb solution onto the tissue section and incubate at RT for 30 min.

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: PEG precipitation

Clonality: Monoclonal

Clone: IPO-38

Isotype: IgM, kappa

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide

Concentration: 0.2 mg/mL

Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.

Alternate Name: N/A

User Note: Optimal dilutions for each application to be determined by the researcher

BACKGROUND: Recognizes a protein of 14-16kDa, which is a novel nuclear antigen of proliferating cells. IPO38 antigen is present in the nuclei of proliferating cells such as Hodgkin s disease and non-Hodgkin s lymphomas, different forms of leukemias, breast and colorectal carcinomas, and PHA-stimulated lymphocytes. It is not expressed in the cells of non-stimulated lymphocytes and granulocytes. IPO38 may be a useful marker of cell proliferation during monitoring of tumor progression.